Idalazide (Olmesartan Medoxomil, Hydrochlorothiazide)

Idalazide is an antihypertensive medication that acts on the renin‑angiotensin system and promotes diuresis to lower blood pressure.

• Hypertension: reduces systolic and diastolic blood pressure and helps prevent cardiovascular complications.
• Essential high blood pressure: provides sustained control when monotherapy is insufficient.
• Elevated arterial pressure: improves overall hemodynamic stability.

• Olmesartan medoxomil selectively blocks the AT1 receptor, preventing angiotensin II‑mediated vasoconstriction and aldosterone release. Hydrochlorothiazide inhibits NaCl reabsorption in the distal convoluted tubule, increasing urinary sodium and water excretion, which together lower peripheral resistance and plasma volume, resulting in reduced blood pressure.

Common Side Effects

• Dizziness: transient light‑headedness, especially after the first dose.
• Headache: mild to moderate intensity.
• Fatigue: general tiredness without exertion.
• Increased urination: due to the diuretic component.
• Electrolyte imbalance: mild changes in potassium or sodium levels.
• Cough: occasional dry throat irritation.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure causing fainting.
• Acute kidney injury: sudden reduction in renal function.
• Hyperkalemia: elevated potassium that may affect heart rhythm.
• Angioedema: swelling of face, lips, or airway.
• Pancreatitis: abdominal pain with elevated enzymes.
• Liver dysfunction: abnormal liver enzyme elevations.

Before initiating Idalazide, consider the following precautions:

• Blood pressure monitoring: ensure target levels are achieved without excessive drop.
• Renal function assessment: evaluate serum creatinine and eGFR regularly.
• Electrolyte surveillance: check potassium and sodium levels, especially with concomitant drugs.
• Pregnancy safety: avoid use unless benefits outweigh potential risks, as safety data are limited.
• Drug‑specific contraindications: do not use in patients with known hypersensitivity to either component.
• Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and direct sunlight.

Idalazide may interact with several medicines; awareness of these interactions helps maintain safety and efficacy.

Major Interactions (Avoid)

• Aliskiren: combined use can cause severe hypotension and renal impairment.
• Potassium‑sparing diuretics or supplements: risk of hyperkalemia.
• Lithium: increased lithium levels may lead to toxicity.
• ACE inhibitors or other ARBs: additive blood‑pressure lowering effect, may cause hypotension.
• NSAIDs: can blunt antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may enhance blood‑pressure reduction.
• Calcium channel blockers: additive hypotensive effect.
• Antidiabetic agents: diuretic may affect glucose control.
• Antimicrobials (e.g., trimethoprim): may increase risk of electrolyte disturbances.